Pharmaceuticals Acquisitions in New Jersey
New Jersey Pharmaceuticals Deal Threads
New Jersey has been a recurring focal point for pharmaceuticals deal activity, ranging from blockbuster-focused buyers like Johnson & Johnson to CDMO and specialty operators expanding manufacturing and development capabilities.
Across the transactions, a clear theme is operational capability growth—especially in drug product manufacturing, clinical trial materials supply, and related development services. Deals also include specialty product and IP acquisitions that can broaden therapeutic portfolios and extend treatment access during transitions.
Recurring financial and strategic participants—such as Azurity Pharmaceuticals, Inc., ANI Pharmaceuticals, Inc., Ardena, Olympus Partners, and H.I.G. Capital—show that New Jersey participation spans both platform-building investments and targeted capability add-ons at specific facilities.
What Stands Out
- CDMO and clinical trial supply capacity appear repeatedly, including additions to fill-and-finish, drug product manufacturing, and biomanufacturing-adjacent services in New Jersey.
- Facility-level acquisitions stand out, such as Ardena acquiring Catalent’s Somerset drug product facility and Aptar Pharma adding Boonton clinical trial materials manufacturing capabilities.
- Specialty product and IP deals also feature, including Johnson & Johnson adding CAPLYTA via the acquisition of Intra-Cellular Therapies and Cosette Pharmaceuticals acquiring Vyleesi and related intellectual property.
- Private equity and investment platforms are active alongside strategics, with recurring names like Azurity Pharmaceuticals, Inc., Ardena, Olympus Partners, and funds managed by Hamilton Lane.
| Buyer type | What deals often add |
|---|---|
| Strategic pharma | Approved products and clinical-stage pipelines |
| CDMO/supply services | Drug product manufacturing, clinical trial materials, and downstream services |
| Specialty pharma & investors | Product/IP ownership to expand portfolios |
| Platform investors | Balance-sheet strengthening and growth strategy support |
-
July 15, 2025
- Buyer
- Aptar Pharma (AptarGroup, Inc.)
- Target
- Mod3 Pharma (formerly Enteris Biopharma) - clinical trial materials manufacturing capabilities
- Seller
- SWK Holdings
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Divestiture
Aptar Pharma has acquired the Phase 1 and 2 clinical trial materials manufacturing capabilities of Mod3 Pharma (formerly Enteris Biopharma) from SWK Holdings. The deal adds cGMP fill-and-finish, high-potency API suites and biologics capabilities at a Boonton, New Jersey facility to Aptar's drug delivery and early-stage development services to accelerate adoption of its delivery technologies.
-
- Buyer
- Kaken Pharmaceuticals, KAKEN INVESTMENTS INC.
- Target
- Aadi Subsidiary, Inc.
- Seller
- Aadi Bioscience, Inc., Whitehawk Therapeutics, Inc.
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Divestiture
Whitehawk Therapeutics completed the divestiture of Aadi Subsidiary, Inc. (including the Aadi Bioscience name, trademarks, and the FYARRO (sirolimus protein-bound particles for injectable suspension) business) to Kaken Pharmaceuticals for $100 million in cash plus customary adjustments. Whitehawk plans to use proceeds (along with a $100M PIPE financing) to develop its ADC portfolio and for general corporate and working capital needs.
-
February 24, 2025
- Buyer
- Olympus Partners
- Target
- PAI Pharma
- Seller
- Enhanced Healthcare Partners, Bourne Partners Strategic Capital
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Buyout
Olympus Partners has acquired PAI Pharma, a leading U.S. developer, manufacturer and distributor of generic oral liquid medicines. The platform was previously owned by Enhanced Healthcare Partners and Bourne Partners Strategic Capital; terms were not disclosed and Monroe Capital provided senior financing for the deal.
-
October 29, 2024
- Buyer
- 1315 Capital, East Seattle Partners, Harro Höfliger Packaging Systems, Inc., Kineticos Ventures
- Target
- Experic
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Growth capital
Experic, a Cranbury, New Jersey-based CDMO and clinical trial supply services firm, received a growth capital investment led by 1315 Capital with participation from existing investors East Seattle Partners, Harro Höfliger Packaging Systems, Inc., and Kineticos Ventures. The capital will be used to enhance Experic’s manufacturing capabilities and accelerate its international expansion to better serve biopharmaceutical clients.
-
- Buyer
- Ardena, GHO Capital Partners LLP
- Target
- Catalent (Somerset, New Jersey manufacturing facility)
- Seller
- Catalent
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Addon
Ardena, a GHO Capital-backed CDMO, has signed a definitive agreement to acquire Catalent's FDA-approved drug product manufacturing facility in Somerset, New Jersey. The acquisition — expected to close in early 2025 subject to approvals — expands Ardena's US footprint and downstream capabilities in oral solid dosage manufacturing and bioanalytical services.
-
October 7, 2024
- Buyer
- Actylis
- Target
- Pharm-Rx
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Buyout
Actylis has acquired Pharm-Rx, a Saddle Brook, New Jersey-based supplier of specialty ingredients for the vitamin, mineral and supplement (VMS), OTC and pharmaceutical markets. The deal expands Actylis' nutrition and OTC capabilities and supplier partnerships; Pharm-Rx will continue to operate under its brand and Mark Bostel will become President, Global Nutrition and OTC for Actylis. Financial terms were not disclosed.
-
July 17, 2024
- Buyer
- Funds managed by Hamilton Lane
- Target
- Cosette Pharmaceuticals
- Seller
- Avista Capital Partners, Avista's co-investors
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Growth capital
Funds managed by Hamilton Lane have acquired a significant equity interest in Cosette Pharmaceuticals from Avista Capital Partners and its co-investors. Avista and Hamilton Lane will jointly control Cosette as the company strengthens its balance sheet to accelerate R&D, product innovation and future M&A activity.
-
- Buyer
- Cosette Pharmaceuticals, Inc., Avista Healthcare Partners
- Target
- Vyleesi (bremelanotide injection)
- Seller
- Palatin Technologies, Inc.
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Divestiture
Cosette Pharmaceuticals, a U.S. specialty pharmaceutical company backed by Avista Healthcare Partners, has acquired the Vyleesi (bremelanotide) product and related intellectual property from Palatin Technologies. The deal transfers five Orange Book-listed patents (protection through 2041) and aims to expand Cosette’s women's health portfolio while ensuring continued patient access during the transition.
-
- Buyer
- Noramco
- Target
- Cambrex Drug Product Business Unit (formerly Halo Pharmaceuticals)
- Seller
- Cambrex
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Divestiture
Noramco has completed the acquisition of the Cambrex Drug Product Business Unit (previously Halo Pharmaceuticals), adding drug product formulation development, clinical and commercial manufacturing, and packaging capabilities from sites in Mirabel, Québec and Whippany, New Jersey. The purchase expands Noramco's service offering beyond APIs, brings nearly 400 employees into the Noramco group, and represents Cambrex's strategic divestiture to focus on its drug substance and analytical testing businesses.
-
October 2, 2023
- Buyer
- Advent International, Warburg Pincus
- Target
- Simtra BioPharma Solutions
- Seller
- Baxter International Inc.
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Divestiture
Advent International and Warburg Pincus completed the acquisition of Baxter International's BioPharma Solutions (BPS) business for $4.25 billion in cash, creating a standalone CDMO named Simtra BioPharma Solutions. Simtra will operate manufacturing sites in Bloomington, Indiana and Halle, Germany, establish a corporate headquarters in New Jersey, and employ approximately 1,700 people to provide sterile contract manufacturing and parenteral delivery services to pharma and biotech customers.
-
September 27, 2023
- Buyer
- Azurity Pharmaceuticals, Inc.
- Target
- Slayback Pharma LLC
- Seller
- KKR, Everstone Capital
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Addon
Azurity Pharmaceuticals has completed the acquisition of Slayback Pharma LLC from existing investors including KKR and Everstone Capital, making Slayback a wholly owned subsidiary of Azurity. The deal expands Azurity's R&D and complex formulation capabilities and accelerates its pipeline for new medicine launches as part of its growth strategy under majority owner QHP Capital.
-
September 26, 2023
- Buyer
- Alfasigma S.p.A.
- Target
- Intercept Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Buyout
Alfasigma S.p.A. entered into a definitive merger agreement to acquire Intercept Pharmaceuticals, Inc. for $19.00 per share in cash, representing an 82% premium to Intercept’s closing price on September 25, 2023. The deal is structured as a cash tender offer followed by a second-step merger and is expected to close by the end of 2023, pending conditions including a minimum tender and regulatory requirements.
-
June 15, 2023
- Buyer
- RK Pharma Inc
- Target
- VGYAAN Pharmaceuticals LLC
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Buyout
RK Pharma Inc., a vertically integrated pharmaceutical company based in Pearl River, New York, has completed the acquisition of VGYAAN Pharmaceuticals LLC, a specialty pharmaceutical company headquartered in Skillman, New Jersey. The deal brings VGYAAN's product portfolio and experienced management team into RK Pharma's vertically integrated platform, enhancing capabilities across complex product development, APIs and finished-dosage manufacturing; terms were not disclosed.
-
October 25, 2022
- Buyer
- Symeres, Keensight Capital
- Target
- Exemplify BioPharma
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Addon
Symeres, a Netherlands-headquartered transatlantic CRO/CDMO majority‑owned by Keensight Capital, has acquired Exemplify BioPharma, a Cranbury, New Jersey-based CMC-focused CRO. The deal strengthens Symeres' capabilities in process and analytical chemistry and formulation development and further expands its strategic foothold in the United States.
-
April 13, 2022
- Buyer
- Halozyme Therapeutics, Inc.
- Target
- Antares Pharma, Inc.
- Seller
- Antares shareholders
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Buyout
Halozyme Therapeutics will acquire Antares Pharma for $5.60 per share in cash, valuing Antares at approximately $960 million. The deal, approved unanimously by both boards, is intended to expand Halozyme's drug delivery capabilities by adding Antares' auto-injector platform and commercial specialty products and is expected to be accretive to Halozyme's 2022 revenue and non-GAAP earnings.
-
February 3, 2022
- Buyer
- APNAR Pharma LP
- Target
- Aurex Laboratories
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Buyout
APNAR Pharma LP, a privately owned pharmaceutical company based in Chino, California, has acquired East Windsor, New Jersey–based Aurex Laboratories. The deal adds US FDA–approved finished dosage manufacturing capabilities to APNAR’s platform, expanding its U.S. footprint, pipeline capacity and contract manufacturing capabilities to support APNAR’s ANDAs and third‑party partners.
-
- Buyer
- H.I.G. Capital
- Target
- Rising Pharma Holdings, Casper Pharma
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Growth capital
An affiliate of H.I.G. Capital has made a strategic equity investment in Rising Pharma Holdings and Casper Pharma (together, Rising Pharmaceuticals) to support the company's growth, M&A activity and new product launches. Rising Pharmaceuticals is an asset-light developer and marketer of generic and specialty pharmaceuticals based in New Jersey with a diversified portfolio of over 125 products and a network of 23+ CMO/CDO partners.
-
August 30, 2021
- Buyer
- Alora Pharmaceuticals, LLC
- Target
- Osmotica Pharmaceutical US LLC, Vertical Pharmaceuticals, LLC, Trigen Laboratories, LLC, Marietta, Georgia manufacturing facility (Osmotica)
- Seller
- Osmotica Pharmaceuticals plc
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Divestiture
Alora Pharmaceuticals, LLC closed the acquisition of Osmotica Pharmaceuticals plc's legacy U.S. business (including Osmotica Pharmaceutical US LLC, Vertical Pharmaceuticals, LLC and Trigen Laboratories, LLC) and the Marietta, Georgia manufacturing facility on August 27, 2021. Osmotica received approximately $111 million in proceeds, which it said would be used to retire a substantial portion of outstanding debt and to focus the company on its ophthalmic product UPNEEQ.
-
- Buyer
- Aztiq Pharma Partners
- Target
- Alvogen US
- Seller
- Alvogen Lux Holdings
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Growth capital
Aztiq Pharma Partners completed a $100 million financing to acquire a newly issued 17% equity stake in Alvogen US at a pre-money valuation of $350 million, with Morgan Stanley leading the financing. The funding will support increased R&D investment and expansion of branded sales channels in the U.S., and following the transaction Aztiq holds a combined direct and indirect stake of approximately 40% in Alvogen US.
-
- Buyer
- Signet Healthcare Partners
- Target
- Ascendia Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Growth capital
Signet Healthcare Partners, a New York-based growth equity firm, has made a growth equity investment in Ascendia Pharmaceuticals, a North Brunswick, New Jersey-based specialty CDMO. The proceeds will fund Ascendia's facility expansion and increased manufacturing capacity; Signet principals James Gale and Dr. Theron Odlaug will join Ascendia's board.
-
March 9, 2021
- Buyer
- ANI Pharmaceuticals, Inc., Ampersand Capital Partners
- Target
- Novitium Pharma
- Seller
- Novitium Pharma shareholders (including founders Samy Shanmugam, Chad Gassert and Vijay Thorappadi)
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Buyout
ANI Pharmaceuticals completed the acquisition of Novitium Pharma for $163.5 million (including $89.5M cash and $74M equity, plus up to $46.5M in contingent earn-outs), adding a U.S.-based R&D engine and CDMO manufacturing capacity. The deal, financed with a new $300M Term Loan B, a $40M revolver and a $25M PIPE investment from Ampersand Capital Partners, is expected to be immediately accretive and expand ANI's generics, contract manufacturing and 505(b)(2) capabilities.
-
June 5, 2020
- Buyer
- UCB
- Target
- Engage Therapeutics
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Buyout
Belgium-based biopharma UCB has acquired Summit, New Jersey-based Engage Therapeutics for an upfront cash payment of US$125 million plus up to US$145 million in milestone payments, gaining worldwide rights to Staccato Alprazolam. The acquisition adds a late-stage, drug-device rescue therapy candidate for epilepsy to UCB's neurology portfolio and includes updated license and supply agreements with Alexza Pharmaceuticals.
-
January 28, 2020
- Buyer
- BioPharmX Corporation
- Target
- Timber Pharmaceuticals LLC
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Buyout
BioPharmX Corporation (NYSE American: BPMX) entered into a definitive merger agreement with Timber Pharmaceuticals LLC whereby a BioPharmX subsidiary will merge into Timber, leaving Timber as a wholly‑owned subsidiary of BioPharmX. The transaction will bring at least $20 million of financing to the combined company, after which BioPharmX will change its name to Timber Pharmaceuticals and Timber’s management will become the combined company's leadership.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.
Frequently Asked Questions
What kinds of pharmaceuticals acquisitions are most visible in New Jersey?
Recent deals highlight (1) CDMO and clinical trial materials manufacturing capability adds and (2) specialty product/IP acquisitions—often tied to specific New Jersey facilities or marketed products.
Which acquisitions in New Jersey involve manufacturing or CDMO capabilities?
Examples include Aptar Pharma adding Phase 1/2 clinical trial materials manufacturing capabilities in Boonton and Ardena acquiring Catalent’s Somerset, New Jersey drug product facility (Oral solid dosage and bioanalytical services).
Are New Jersey deals limited to strategics like major pharma companies?
No. The list also features investment firms and platforms such as Olympus Partners, Hamilton Lane (fund-managed), and other recurring buyers, alongside strategic pharma.
Do any acquisitions relate to specific products and intellectual property?
Yes. Cosette Pharmaceuticals acquired Vyleesi (bremelanotide) and related intellectual property from Palatin Technologies, and Johnson & Johnson acquired Intra-Cellular Therapies to add the approved drug CAPLYTA and a neuroscience pipeline.